Clark Capital Management Group, Inc.
Position in LGND — Ligand Pharmaceuticals Inc
CIK 1352187
PHILADELPHIA, PA
Position in LGND
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$18,009,627
+$2,926,001 QoQ
Shares Held
90,206
+13.1% QoQ
Ownership
0.450%
of shares outstanding
% of Portfolio
0.15%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 99.9090969558566.ToString("F0")%
Shared 0.ToString("F0")%
None 0.0909030441434051.ToString("F0")%
Common Shares in LGND Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Clark Capital Management Group, Inc. holds $130,946,596 across 6 Biotechnology names. LGND ranks #2 (13.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
|
1,639,968 | $78,669,264 | |
| 2 | LGND |
Ligand Pharmaceuticals Inc
This page
|
90,206 | $18,009,627 | |
| 3 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
568,676 | $14,080,417 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
214,102 | $13,837,412 | |
| 5 | EXEL |
Exelixis, Inc.
|
142,980 | $6,132,412 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
487 | $217,464 |
All Filings in LGND
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $18,009,627 | 90,206 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $15,083,626 | 79,778 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $14,701,025 | 82,991 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $8,086,399 | 71,133 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $4,631,837 | 44,054 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $3,994,230 | 37,277 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $2,584,423 | 25,821 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||